Ziv, Yarden
Rahamim, Nofar
Lezmy, Noa
Even-Chen, Oren
Shaham, Ohad
Malishkevich, Anna
Giladi, Eliezer
Elkon, Ran
Gozes, Illana http://orcid.org/0000-0001-9796-2430
Barak, Segev http://orcid.org/0000-0002-3143-6777
Funding for this research was provided by:
Israel Science Foundation (ISF) (1424/14, 968-13, 1916-13)
German-Israeli Foundation for Scientific Research and Development (GIF) (I-2348-105.4/2014)
Article History
Received: 25 June 2017
Revised: 20 June 2018
Accepted: 21 June 2018
First Online: 27 June 2018
Competing interests
: . NAP (also known as davunetide, CP201), under patent protection (IG), is being developed, under agreement with Ramot at Tel Aviv University, by Coronis Neurosciences for the ADNP syndrome (IG Chief Scientific Officer).